Re: Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

Patrick C. Walsh

doi:10.1016/j.juro.2012.04.072

Re: Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	430-431
Number of pages	2
Journal	Journal of Urology
Volume	188
Issue number	2
DOIs	https://doi.org/10.1016/j.juro.2012.04.072
State	Published - Aug 1 2012
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2012.04.072

Cite this

@article{1e3d7d7303cf4075aea42d952507c983,

title = "Re: Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer",

author = "Walsh, {Patrick C.}",

year = "2012",

month = aug,

day = "1",

doi = "10.1016/j.juro.2012.04.072",

language = "English (US)",

volume = "188",

pages = "430--431",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Re

T2 - Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

AU - Walsh, Patrick C.

PY - 2012/8/1

Y1 - 2012/8/1

UR - http://www.scopus.com/inward/record.url?scp=84863692551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863692551&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.04.072

DO - 10.1016/j.juro.2012.04.072

M3 - Comment/debate

C2 - 22784723

AN - SCOPUS:84863692551

SN - 0022-5347

VL - 188

SP - 430

EP - 431

JO - Journal of Urology

JF - Journal of Urology

IS - 2

ER -

Re: Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this